Expression of LDH mRNA in vascular smooth muscle cells: Differential effects of platelet-derived growth factor and angiotensin II  by Altmann, Dory B. et al.
JACC Vol. 17. E;o. 2 
February 1991: I 39A 
Comparative Effects of WLFS-49 and Verapamil 
Rate and Contractfllty fn Isola ted Hearts 
on Heart 
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Harvard-Thorndike Laboratory, Beth Israel Hospital, 
Boston, MA 
ULFS-49 is a new drug believed to selectively block 
sinoatrial node Cat+ channels. We compared the effects 
of ULFS-49 to its structural analog, verapamil (VERAP), 
in isolated, blood perfused pig hearts with an 
isovolumic left ventricle (LV). LV function was 
evaluated by changes in peak systolic pressure (PLVP, 
dr3) and q axinum dP/dt normalized by PLVP 
((dP/dt)/P,sec-') . After control (CONT) measurements, 
doses of ULFS-49 or VERAP were increased cumulatively 
until either a 30% decrease in heart rate (HR. 
beats/fain) or a 50% decrease in PLVP was achieved. 
Hearts remained in sinus rhythm throughout. 
Group I (n-6) Group II (n-6) 
CONT ULFS-49 CONT VERAPAY L 
HR 14328 99+4* 136?7 120+7* 
PLVP 104+5 9524 10023 45-+4* 
(dP/dt)/P 8.52.9 7.32.9 8.15.5 4.9+.2* 
*p<.OS vs control; mean 2 S.E. 
These results indicate that that ULFS-49 decreases HR 
to a much greater extent than VERAP, with minor effects 
on LV inotropy in the isolated, blood perfused pig 
heart. Conclusion: ULFS-49 is a highly selective 
bradycardic agent and may prove useful in the treatment 
of ischemic heart disease and congestive heart failure. 
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